^
Association details:
| Biomarker: | RAB5A expression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RAB5 is a generic biomarker for ADC efficacy
Published date:
11/22/2022
Excerpt:
The early endosome marker RAB5A, was found to correlate positively to the activity of trastuzumab deruxtecan, sacituzumab govitecan….in the HER2 positive cell line panel, confirming the importance of RAB5A expression for the activity of these drugs.
